Treatment of Ascariasis
For ascariasis, treat with a single dose of albendazole 400 mg PO, mebendazole 500 mg PO, or ivermectin 200 μg/kg PO—all three options are equally effective with cure rates exceeding 93%. 1
First-Line Treatment Options
The 2025 UK guidelines provide three equivalent single-dose regimens 1:
- Albendazole 400 mg PO (single dose)
- Mebendazole 500 mg PO (single dose)
- Ivermectin 200 μg/kg PO (single dose)
All three agents achieve parasitological cure rates of 93-98% at 14-60 days post-treatment, with egg reduction rates of 96-100% 2. A 2020 Cochrane review of 30 RCTs involving 6,442 participants found no significant differences in efficacy between these drugs (high-certainty evidence) 2.
Key Clinical Considerations
Drug Selection
- Single doses are as effective as multiple doses for albendazole (cure rate 93.2% vs 94.3%; high-certainty evidence) 2
- Choose based on availability and patient factors—there is no superior option among the three
- Treatment failure rates are low across all agents: albendazole 0-30.3%, mebendazole 0-22.2%, ivermectin 0-21.6% 2
Special Populations
Pregnant Women:
- Use pyrantel pamoate in pregnancy rather than albendazole or mebendazole 3
- However, if albendazole is used, it demonstrates high cure rates (up to 90% for Ascaris) and appears safe with no increased pregnancy loss or preterm delivery 4
- Mebendazole shows lower cure rates (≤70%) in pregnancy 4
Children:
- Albendazole and mebendazole are drugs of choice 3
- For children 12-24 months, discuss with an expert before empirical treatment 1
- Children >24 months can receive standard adult dosing 1
Important Precautions
Before using ivermectin:
- Exclude Loa loa infection in patients who have traveled to endemic regions (Central/West Africa) to prevent serious adverse reactions 1
Treat even asymptomatic patients to prevent complications including intestinal obstruction, biliary obstruction, and migration-related issues 3
Diagnosis
- Concentrated stool microscopy or fecal PCR are the diagnostic methods of choice 1
- Patients may report passing earthworm-sized pink or white adult worms in stool or via regurgitation 1
Safety Profile
No serious adverse events have been attributed to any of these anthelmintics 2. Common minor adverse events include:
- Nausea, vomiting
- Abdominal pain, diarrhea
- Headache, fever
These occur at similar rates across all treatment groups (moderate- to low-certainty evidence) 2.
Follow-Up Considerations
- Average cure rate exceeds 95% with single-dose treatment 3
- Reinfection is common in endemic areas, often occurring within months 3
- Consider repeat stool examination if symptoms persist, though routine post-treatment testing is not typically necessary for uncomplicated cases
- In endemic regions, combine treatment with health education, improved sanitation, and proper disposal of human waste 3
Clinical Pitfalls
- Don't delay treatment waiting for diagnostic confirmation if clinical suspicion is high and patient is symptomatic
- Remember that heavy infections can cause serious complications (intestinal obstruction in children, biliary obstruction in adults) requiring surgical intervention 1, 3, 5
- Prevalence remains highest in children under 5 years in tropical/subtropical regions with poor sanitation 3, 6